BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20171036)

  • 21. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry.
    Rodriguez AE; Maree AO; Mieres J; Berrocal D; Grinfeld L; Fernandez-Pereira C; Curotto V; Rodriguez-Granillo A; O'Neill W; Palacios IF
    Eur Heart J; 2007 Sep; 28(17):2118-25. PubMed ID: 17656352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.
    Abizaid A; Costa JR; Banning A; Bartorelli AL; Dzavik V; Ellis S; Gao R; Holmes DR; Jeong MH; Legrand V; Neumann FJ; Nyakern M; Orlick A; Spaulding C; Worthley S; Urban PM;
    JACC Cardiovasc Interv; 2012 Jan; 5(1):64-71. PubMed ID: 22230152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry.
    Kim BK; Oh S; Jeon DW; Yang JY; Kim JS; Park S; Choi D; Jang Y; Hong BK; Kwon HM; Lee SW; Goh CW; Kwon K; Ryu SK;
    J Interv Cardiol; 2009 Oct; 22(5):411-9. PubMed ID: 19702679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.
    Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Yamaji K; Ando K; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Kato M; Suwa S; Takizawa A; Takatsu Y; Shinoda E; Eizawa H; Takeda T; Lee JD; Inoko M; Ogawa H; Hamasaki S; Horie M; Nohara R; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
    Circ Cardiovasc Interv; 2014 Apr; 7(2):168-79. PubMed ID: 24550439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
    Violini R; Musto C; De Felice F; Nazzaro MS; Cifarelli A; Petitti T; Fiorilli R
    J Am Coll Cardiol; 2010 Feb; 55(8):810-4. PubMed ID: 20170821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender-specific outcomes after sirolimus-eluting stent implantation.
    Solinas E; Nikolsky E; Lansky AJ; Kirtane AJ; Morice MC; Popma JJ; Schofer J; Schampaert E; Pucelikova T; Aoki J; Fahy M; Dangas GD; Moses JW; Cutlip DE; Leon MB; Mehran R
    J Am Coll Cardiol; 2007 Nov; 50(22):2111-6. PubMed ID: 18036446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
    Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
    J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
    Schampaert E; Cohen EA; Schlüter M; Reeves F; Traboulsi M; Title LM; Kuntz RE; Popma JJ;
    J Am Coll Cardiol; 2004 Mar; 43(6):1110-5. PubMed ID: 15028375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
    Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
    JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial.
    Valgimigli M; Dawkins K; Macaya C; de Bruyne B; Teiger E; Fajadet J; Gert R; De Servi S; Ramondo A; Wittebols K; Stoll HP; Rademaker TA; Serruys PW
    J Am Coll Cardiol; 2007 Jan; 49(4):431-41. PubMed ID: 17258088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.
    Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
    J Am Coll Cardiol; 2018 Jul; 72(4):386-398. PubMed ID: 30025574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.